Insider Trading Alert - SWI, ADBE, GLUU, NBIX And AXE Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 8, 2014, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.20 to $12,860,510.00.

Highlighted Stocks Traded by Insiders:

SolarWinds (SWI) - FREE Research Report

Sims Bryan Allen who is SVP, General Csl & Secretary at SolarWinds sold 8,599 shares at $38.88 on Jan. 8, 2014. Following this transaction, the SVP, General Csl & Secretary owned 25,865 shares meaning that the stake was reduced by 24.95% with the 8,599-share transaction.

The shares most recently traded at $39.98, up $1.10, or 2.76% since the insider transaction. Historical insider transactions for SolarWinds go as follows:

  • 4-Week # shares bought: 10,000
  • 12-Week # shares bought: 10,000
  • 24-Week # shares bought: 20,000

The average volume for SolarWinds has been 1.2 million shares per day over the past 30 days. SolarWinds has a market cap of $2.9 billion and is part of the technology sector and computer software & services industry. Shares are up 3.97% year-to-date as of the close of trading on Wednesday.

SolarWinds, Inc. designs, develops, markets, sells, and supports enterprise-class information technology (IT) and infrastructure management software to IT professionals in various organizations worldwide. The company has a P/E ratio of 32.8. Currently there are 4 analysts that rate SolarWinds a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWI - FREE

TheStreet Quant Ratings rates SolarWinds as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full SolarWinds Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Adobe Systems (ADBE) - FREE Research Report

Garrett Mark who is EVP, CFO & Asst. Secretary at Adobe Systems sold 11,899 shares at $58.20 on Jan. 8, 2014. Following this transaction, the EVP, CFO & Asst. Secretary owned 107 shares meaning that the stake was reduced by 99.11% with the 11,899-share transaction.

The shares most recently traded at $59.29, up $1.09, or 1.84% since the insider transaction. Historical insider transactions for Adobe Systems go as follows:

  • 4-Week # shares sold: 3,010
  • 12-Week # shares sold: 25,750
  • 24-Week # shares sold: 80,750

The average volume for Adobe Systems has been 3.9 million shares per day over the past 30 days. Adobe Systems has a market cap of $29.5 billion and is part of the technology sector and computer software & services industry. Shares are down 1.64% year-to-date as of the close of trading on Wednesday.

Adobe Systems Incorporated operates as a diversified software company worldwide. The company operates in three segments: Digital Media, Digital Marketing, and Print and Publishing. The company has a P/E ratio of 44.0. Currently there are 8 analysts that rate Adobe Systems a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADBE - FREE

TheStreet Quant Ratings rates Adobe Systems as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Adobe Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Glu Mobile (GLUU) - FREE Research Report

Nada Hany who is Director at Glu Mobile sold 500,000 shares at $4.15 on Jan. 8, 2014. Following this transaction, the Director owned 93,680 shares meaning that the stake was reduced by 84.22% with the 500,000-share transaction.

The shares most recently traded at $4.34, up $0.19, or 4.39% since the insider transaction.

The average volume for Glu Mobile has been 3.4 million shares per day over the past 30 days. Glu Mobile has a market cap of $325.1 million and is part of the technology sector and computer software & services industry. Shares are up 9.51% year-to-date as of the close of trading on Wednesday.

Glu Mobile Inc. develops and publishes a portfolio of action/adventure and casual games for the users of smartphones and tablet devices. Currently there are 5 analysts that rate Glu Mobile a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GLUU - FREE

TheStreet Quant Ratings rates Glu Mobile as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. Get the full Glu Mobile Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Neurocrine Biosciences (NBIX) - FREE Research Report

Gorman Kevin Charles who is President and CEO at Neurocrine Biosciences sold 108,000 shares at $16.76 on Jan. 8, 2014. Following this transaction, the President and CEO owned 177,202 shares meaning that the stake was reduced by 37.87% with the 108,000-share transaction.

OBrien Christopher Flint who is Chief Medical Officer at Neurocrine Biosciences sold 5,000 shares at $17.50 on Jan. 8, 2014. Following this transaction, the Chief Medical Officer owned 94,794 shares meaning that the stake was reduced by 5.01% with the 5,000-share transaction.

Coughlin Timothy P who is Chief Financial Officer at Neurocrine Biosciences sold 70,000 shares at $16.75 on Jan. 8, 2014. Following this transaction, the Chief Financial Officer owned 96,124 shares meaning that the stake was reduced by 42.14% with the 70,000-share transaction.

Bozigian Haig P. who is Chief Development Officer at Neurocrine Biosciences sold 25,000 shares at $17.50 on Jan. 8, 2014. Following this transaction, the Chief Development Officer owned 76,954 shares meaning that the stake was reduced by 24.52% with the 25,000-share transaction.

Grigoriadis Dimitri E. who is Chief Research Officer at Neurocrine Biosciences sold 25,000 shares at $17.50 on Jan. 8, 2014. Following this transaction, the Chief Research Officer owned 75,433 shares meaning that the stake was reduced by 24.89% with the 25,000-share transaction.

The shares most recently traded at $18.15, up $0.65, or 3.58% since the insider transaction. Historical insider transactions for Neurocrine Biosciences go as follows:

  • 12-Week # shares sold: 2,400
  • 24-Week # shares sold: 82,531

The average volume for Neurocrine Biosciences has been 947,200 shares per day over the past 30 days. Neurocrine Biosciences has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 93.58% year-to-date as of the close of trading on Wednesday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently there are 10 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBIX - FREE

TheStreet Quant Ratings rates Neurocrine Biosciences as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Neurocrine Biosciences Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Anixter International (AXE) - FREE Research Report

Faber Terrance who is VP-Controller at Anixter International sold 700 shares at $89.66 on Jan. 8, 2014. Following this transaction, the VP-Controller owned 21,803 shares meaning that the stake was reduced by 3.11% with the 700-share transaction.

The shares most recently traded at $91.93, up $2.27, or 2.47% since the insider transaction. Historical insider transactions for Anixter International go as follows:

  • 4-Week # shares sold: 500
  • 12-Week # shares sold: 15,235
  • 24-Week # shares sold: 34,465

The average volume for Anixter International has been 151,700 shares per day over the past 30 days. Anixter International has a market cap of $2.9 billion and is part of the services sector and wholesale industry. Shares are up 1.85% year-to-date as of the close of trading on Wednesday.

Anixter International Inc., together with its subsidiaries, distributes enterprise cabling and security solutions, electrical and electronic wire and cable products, original equipment manufacturer (OEM) supply fasteners, and other small parts. The company has a P/E ratio of 20.3. Currently there are 4 analysts that rate Anixter International a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AXE - FREE

TheStreet Quant Ratings rates Anixter International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, good cash flow from operations, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Anixter International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home